Phototoxicity of Lumidoxycycline

Shea, Christopher R.; Olack, Gerard; Morrison, Harry; Chen, Norah; Hasan, Tayyaba

doi:10.1111/1523-1747.ep12365484

Cited by 22 publications

(14 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Photo-onycholysis is a rare phototoxic reaction caused by prolonged and intense ultraviolet exposure that results in onycholysis. It has been suggested that doxycycline-induced phototoxicity is associated with lumidoxycycline, which is a photo product of doxycycline (3,4). In our case, the brown nail discoloration with sharp linear edges and the history of intense sun exposure favored a diagnosis of photo-onycholysis.…”

Section: öMer Faruk Elmas 1 Necmettin Akdenizmentioning

confidence: 57%

A Case of Doxycyclin-induced Photo-onycholysis with Dermoscopic Features

Elmas¹,

Akdeniz²

2019

Balkan Med J

View full text Add to dashboard Cite

Section: öMer Faruk Elmas 1 Necmettin Akdenizmentioning

confidence: 57%

A Case of Doxycyclin-induced Photo-onycholysis with Dermoscopic Features

Elmas¹,

Akdeniz²

2019

Balkan Med J

View full text Add to dashboard Cite

“…In the process of cell apoptotic death, the two central pathways are the mitochondrial pathway and the caspase protease pathway (20). In viable cells, doxycycline is transferred into the cytoplasm and localizes in mitochondria, where it is metabolized to stable photoproducts, such as lumidoxycycline, which induces mitochondrial fragmentation and alters mitochondrial membrane integrity, leading to continuous inhibition of mitochondrial protein synthesis (21). Therefore, we firstly assessed the effect of doxycycline on the mitochondrial pathway during the apoptosis induction process.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, caspase-3 is the most important modulator of the caspase protease-mediated apoptosis pathway in mammals. It is regarded as the 'activator' and 'performer' of the caspase protease-mediated apoptosis cascade reaction (21). Survivin is a new member of the anti-apoptosis protein family and is overexpressed in multiple cancer cell lines (23,24).…”

Section: Discussionmentioning

confidence: 99%

New application of an old drug: Antitumor activity and mechanisms of doxycycline in small cell lung cancer

Wang

Zhao

Liu

et al. 2016

International Journal of Oncology

View full text Add to dashboard Cite

Abstract. Small cell lung cancer (SCLC) remains one of the most aggressive tumors with a poor prognosis. The clinical outcome of SCLC patients has reached its plateau with the existing standard treatment and thus new therapies are urgently required. Accumulating evidences have indicated that doxycycline, a commonly used antibiotic, has antitumor activity against several malignancies. However, whether doxycycline has antitumor activity in SCLC and its underlying mechanisms remain unclear. Our investigation demonstrated that doxycycline could significantly inhibit the proliferation and colony formulation of SCLC cells (p<0.05). Furthermore, both Hoechst 33258 dye staining and TUNEL assays indicated that doxycycline could induce remarkable apoptosis of H446 cells in a concentration-dependent manner. RT-PCR and western blot assays proved that apoptosis induction effect of doxycycline was achieved via inducing the expression of caspase-3 and bax, as well as attenuating the expression of survivin and bcl-2. Moreover, the wound healing assay and Transwell assay indicated that doxycycline could significantly suppress the migration and invasion of H446 cells in a concentration-dependent manner (p<0.05). ELISA assay proved that the inhibitory effect of doxycycline on the migration and invasion of H446 cells was achieved via decreasing the secretion of MMP-2, MMP-9 and VEGF, as well as increasing the secretion of TIMP-2. Taken together, doxycycline dose-dependently suppressed the proliferation, colony formulation, migration and invasion of SCLC cells, as well as induced apoptosis. These findings encourage further investigations on the potential of doxycycline as a candidate drug for the treatment of SCLC. IntroductionLung cancer remains the most common cause of cancer-related death worldwide, and was responsible for 1.56 million deaths annually, as of 2012 (1). The main primary types are small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Compared with NSCLC, SCLC has a more aggressive behavior due to its higher proliferative index and tends to spread in its early stages. Combination chemotherapy, generally platinumbased plus etoposide or irinotecan, is the mainstay first-line treatment for metastatic SCLC patients (2,3). Despite the initial sensitivity, the long-term outcomes of the majority of SCLC patients remain poor due to early relapse and acquired resistance (2). In addition, the vast majority of patients with SCLC fail to respond to tyrosine-kinase inhibitors against the epidermal growth factor receptor (EGFR) (4). Except for topotecan, few treatment options then remain (2,5,6). Therefore, it is urgent to develop novel and more effective therapeutic drugs for the treatment of SCLC patients. Doxycycline (DOXY) is a member of the tetracycline family of antibiotics in widespread clinical use. Accumulating evidence has suggested that doxycycline has antitumor activity against several kinds of malignancies. It has been reported that doxycycline has anti-metastatic activity and cytotoxicity in melanoma ...

show abstract

“…Doksisiklinin fototoksik etkileri ultraviyole A ve ultraviyole B ile tetiklenebilir 2 . Doksisiklinin fotosensitivite ve fototoksik reaksiyonlara yol açmasında lumidoksisiklin adı verilen doksisiklin foto ürününün rol aldığı düşünülmektedir 3 . Onikoliz tablosunun ilacın kesilmesini takiben birkaç ay içerisinde gerilediği bildirilmektedir 2 .…”

Section: Discussionunclassified